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Abstract
Locally applied bisphosphonates, such as zoledronate, have been shown in several studies to inhibit
peri-implant bone resorption and recently to enhance peri-implant bone formation. Studies have also
demonstrated positive effects of hydroxyapatite (HA) particles on peri-implant bone regeneration
and an enhancement of the anti-resorptive effect of bisphosphonates in the presence of calcium. In
the present study, both hydroxyapatite nanoparticles (nHA) and zoledronate were combined to
achieve a strong reinforcing effect on peri-implant bone. The nHA–zoledronate combination was ﬁrst
investigated in vitro with a pre-osteoclastic cell assay (RAW 264.7) and then in vivo in a rat model of
postmenopausal osteoporosis. The in vitro study conﬁrmed that the inhibitory effect of zoledronate
on murine osteoclast precursor cells was enhanced by loading the drug on nHA. For the in vivo inves-
tigation, either zoledronate-loaded or pure nHAwere integrated in hyaluronic acid hydrogel. The gels
were injected in screw holes that had been predrilled in rat femoral condyles before the insertion of
miniature screws. Micro-CT-based dynamic histomorphometry and histology revealed an unexpected
rapid mineralization of the hydrogel in vivo through formation of granules, which served as scaffold
for new bone formation. The delivery of zoledronate-loaded nHA further inhibited a degradation of
the mineralized hydrogel as well as a resorption of the peri-implant bone as effectively as unbound
zoledronate. Hyaluronic acid with zoledronate-loaded nHA, thanks to its dual effect on inducing a
rapid mineralization and preventing resorption, is a promising versatile material for bone repair
and augmentation. Copyright © 2015 John Wiley & Sons, Ltd.
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1. Introduction
Zoledronate-loaded hyaluronic acid hydrogel has recently
been shown to efﬁciently improve early bone formation
and inhibit bone resorption around an implant in a rat
model of postmenopausal osteoporosis (Kettenberger
et al., 2014). This is an important ﬁnding, as sufﬁcient
peri-implant bone density is directly linked to successful
implant ﬁxation (Stromsoe et al., 1993; Wilmes et al.,
2006; Wirth et al., 2011). Reliable implant anchorage is,
however, difﬁcult to achieve in patients suffering from
bone diseases that are characterized by a reduced bone
density, such as osteoporosis. Implant migration and revi-
sion surgeries are often the consequence (Lobo-Escolar
et al., 2010). Therefore, the local delivery of a bisphospho-
nate (BP) to the peri-implant bone stock, as demonstrated
with the drug-loaded hydrogel (Kettenberger et al., 2014),
is a promising approach to improve the outcome of
implant ﬁxation in patients presenting low bone quality.
In parallel, other strategies have been shown to success-
fully improve implant anchorage. One of them is the appli-
cation of hydroxyapatite (HA) particles to the implant bed.
Tami et al. (2009) demonstrated that HA particles that are
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ﬁlled into a screw hole are able to induce and maintain a
denser bone mantle around the implant in osteoporotic
bone. HA is chemically similar to the inorganic components
of the bone matrix and therefore exhibits excellent biocom-
patibility with soft and hard tissues (Zhou and Lee, 2011).
It is known to be bioactive, osteoconductive and biodegrad-
able and is therefore widely used as a biomaterial for
dental and orthopaedic applications (LeGeros, 2008).
Considering also the fact that Ca2+ ions have been shown
to enhance the inhibitory effect of nitrogen-containing
BPs on osteoclast precursor cells by enhancing their
endocytic internalization in vitro (Monkkonen et al.,
1994; Thompson et al., 2006), it can be assumed that a
combination of BPs and calcium phosphate particles may
have enhanced effects on bone remodelling.
So far BPs have mainly been absorbed on HA bulk
implants or coatings using the high afﬁnity of the drug
to minerals (Yoshinari et al., 2002; Peter et al., 2006;
Suratwala et al., 2008; Faucheux et al., 2009; Sörensen
et al., 2013). Binding BPs to bulk hydroxyapatite is
associated with a slow release of the drug, as a low pH
is required for a spontaneous release of the drug from a
mineral surface (Rogers et al., 2000; Nancollas et al.,
2006). However, as shown in our previous work, rapid
availability of the BPs seems to be important for a positive
effect on early bone formation (Kettenberger et al., 2014).
The combination of BPs with small enough HA particles
that could be distributed easily in bone and taken up by
osteoclasts seems to be an advantageous idea.
Several studies have investigated the applicability of
BP-loaded nanoparticles for antitumour drug-delivery
properties (Palazzo et al., 2007) and for intravenous
drug-delivery systems (Ong et al., 2008). Boanini et al.
(2012) showed that zoledronate-containing HA nanocrystals
promote osteoblast formation and osteoclast apoptosis
in vitro, but they did not publish comparative results with
pure zoledronate. Nejadnik et al. (2014) recently demon-
strated that BP-functionalized hyaluronic acid containing
calcium phosphate particles is stable in vivo and attracts
bone ingrowth. However, for this study pamidronate was
used only as a chemical link between calcium phosphate
particles and the hydrogel matrix (Wang et al., 2006). In
contrast to the present study, release of the drug to bone
was not intended and was expected to be minimal (Nejadnik
et al., 2014).
In this study we investigated the effect of zoledronate
alone and in the presence of nHA particles on pre-
osteoclastic macrophages in vitro. In a second step, we
evaluated the inﬂuence of hyaluronic acid hydrogel
loaded with nano-sized HA particles and zoledronate on
peri-implant bone formation and resorption in an osteo-
porotic rat model.
2. Materials and methods
Zoledronate was purchased from Enzo Life Sciences (cat.
no. ALX-430-153-0000, Enzo Life Sciences, Farmingdale,
USA). Hydroxyapatite powder (nHA) with a particle size
of ~200nm was bought from Sigma (cat. no. 677418,
Sigma-Aldrich, St. Louis, MO, USA). The nHA particles,
showing a round shape (Figure 1), were heat-sterilized
before use. Cell culture medium (CCM) for the in vitro
studies was prepared by mixing Dulbecco’s modiﬁed
Eagle’s medium (DMEM; cat. no. 41966-029, Gibco, Life
Technologies, Carlsbad, CA, USA) with 10% fetal bovine
serum (FBS; Sigma-Aldrich, cat. no. F7524-500ML), 1%
penicillin–streptomycin (cat. no. 15140122, Gibco) and
1% L-glutamine (cat. no. 25030024, Gibco).
2.1. In vitro cell assay
Murine macrophages (RAW 264.7, passages 13–16) were
used for the present study, as cells from this line are
regarded as osteoclastic precursors (Cuetara et al., 2006)
and have been shown to react in vitro to BP exposure in
a similar way to osteoclasts, and to well tolerate the pres-
ence of HA particles (Scheel et al., 2009; Abe et al., 2012).
An aqueous zoledronate solution with a concentration
of 2mg/ml was prepared and sterile-ﬁltered. The drug
solution was diluted with CCM to ﬁnal concentrations of
10 and 0.625μM zoledronate (Zol assay). The dilution
procedure was repeated with an aqueous dispersion con-
taining 2mg/ml zoledronate and 20mg/ml nHA (nHA–
Zol assay) and a dispersion containing only 20mg/ml
nHA (nHA assay).
Macrophages were seeded at a density of 2500
cells/well in 96-well plates (Microtest™ 96, Becton Dickinson
Labware, NJ, USA), using six wells/group and incubated
with 100μl CCM under standard incubation conditions
(37 °C, 5% CO2). After 24h of incubation, 100μl pure
CCM or one of the six prepared CCMs containing
zoledronate and/or nHA were added to the cells. Seven
experimental groups were therefore included: one control
group with cells exposed only to CCM; two groups
exposed to 0.04 and 1.36μg/ml nHA; two groups exposed
to 0.16 and 5μM zoledronate; and two groups exposed to
either 0.04μg/ml nHA loaded with 0.16μM zoledronate
or 1.36μg/ml nHA loaded with 5μM zoledronate. A cell
Figure 1. Scanning electron microscopy image of the hydroxyap-
atite nanoparticles used for the present study
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proliferation test (CellTitre 96® AQueous One Solution,
Promega, Fitchburg, WI, USA) was performed after 24,
48 and 72h of cell exposure to the modiﬁed CCM. The
absorbance was measured at 490nm using a plate reader
(Wallac 1420 Victor 2, Perkin-Elmer, Waltham, MA,
USA). Background plates with modiﬁed media only were
measured at all time points to avoid a bias caused by
nHA particles in the dispersions. Light images of the cells
were taken using an Axiovert 100 microscope equipped
with an AxioCam MRc camera (both Carl Zeiss AG,
Feldbach, Germany).
2.2. Hydrogel preparation
Commercially available cross-linked hyaluronic acid
(Termira AuxiGel™, Stockholm, Sweden) was used as
the drug-delivery system for particles and zoledronate.
This gel has already been shown to be a suitable drug-
delivery system for BPs (Kettenberger et al., 2014). The
preparation of the hydrogel was done under sterile
conditions in a laminar ﬂow hood. An aqueous solution
containing 2mg/ml zoledronate was prepared and
sterile-ﬁltered. nHA particles were added to the solution
at a nHA:zoledronate ratio of 100:1; the exact drug dose
was ensured by mixing precisely weighed and measured
amounts of zoledronate, nHA and distilled water.
Crosslinking of the hydrogel was achieved by mixing a
hyaluronan derivative (component A) with a PVA cross-
linker (component B); ﬁve parts of the zoledronate–nHA
solution were mixed with three parts component A and
two parts component B for the nHA–Zol–Gel group. The
zoledronate–nHA dispersion was replaced by double-
distilled water with nHA for the nHA–Gel group. The
resulting gels were allowed to settle for 1 h before ﬁlling
the capillary pistons of a positive displacement pipette
(Microman®, Gilson, Middleton, USA) with 5μl gel each.
The capillaries were pulled off the pipette with the gel
inside and left for 1 h for settling, then they were
sterile-packed in plastic tubes and frozen at –20 °C.
2.3. In vivo study
An in vivo study in a rat femoral model of postmenopausal
osteoporosis was performed following a protocol that
was established and published earlier by our group
(Kettenberger et al., 2014). All animal procedures were
approved by the local animal care and use committee
(License No. 2508.1, EXPANIM, SCAV, Epalinges,
Switzerland).
2.3.1. Surgical procedures
Eight virgin female Wistar rats (Janvier Labs, Saint-
Berthevin, France) were ovariectomized bilaterally using
a dorsal approach (Alghamdi et al., 2013) at age 17weeks
and weight of 295±18g to induce an oestrogen
deﬁciency-related bone loss (Hogan et al., 2000). The rats
were housed four/cage under 12 h light:12 h dark cycles
at 22 °C room temperature with 55% humidity. They were
fed a standard rodent diet (Kliba Nafag 3436, Provimi
Kliba AG, Switzerland) and tap water ad libitum. After
ovariectomy (OVX) of the rats, food intake was limited
to 50 g/kg body weight/day. Sterilized hay, paper tunnels
and wooden sticks were offered as cage environment
enrichment. The animals were fed in groups, therefore
an equal nutrition of all animals was ensured by close
monitoring and regular weighing.
One miniature screw was implanted into each femoral
condyle of 22week-old rats with a mean weight of 350
±20g. The screws, with a thread length of 3mm and a di-
ameter of 1.4mm, were custom-made from radio-opaque
polyetheretherketone (PEEK; RISystem, Davos, Switzer-
land) and coated with a 100nm layer of titanium to mimic
the interface with a standard orthopaedic screw. Before
screw insertion, the predrilled unicortical screw holes
(diameter 1.2mm, depth 3.5mm) were ﬁlled with 5μl
of the prepared hydrogel containing only nHA (nHA–Gel
group) or nHA and 5μg zoledronate (nHA–Zol–Gel
group), using a positive displacement pipette. Four ani-
mals were assigned to each group, while both legs of each
animal were treated with the same hydrogel to avoid an
unwanted drug effect on the contralateral side.
2.3.2. In vivo micro-CT imaging and image
processing
In vivo micro-CT scans (Skyscan 1076, Bruker micro-CT,
Kontich, Belgium) of the right femur only were performed
1day before OVX and 1day before screw implantation, in
order to conﬁrm the bone loss caused by the oestrogen de-
ﬁciency. Both femurs were then scanned at days 3, 10, 17,
31, 45 and 58 after screw implantation for the dynamic
histomorphometry. The parameters for data acquisition
and reconstruction were chosen according to our pub-
lished protocol (Kettenberger et al., 2014). The animals
were kept under isoﬂurane anaesthesia during the scan-
ning time to avoid motion artifacts. All rats were eutha-
nized at the time of the last micro-CT scan with an
intraperitoneal injection of pentobarbital (Esconarkon,
Strauli Pharma SA, Uznach) while under anaesthesia.
The image taken for evaluation of the bone loss and for
dynamic histomorphometry were processed and analysed,
using the software Amira® (FEI Vizualisation Sciences
Group, Burlington, USA) and CTan (Bruker micro-CT,
Kontich, Belgium), following a protocol published earlier
(Kettenberger et al., 2014). Dynamic histomorphometry
is an image-processing technique based on registration
and comparison of consecutive micro-CT scans (Waarsing
et al., 2004; Roshan-Ghias et al., 2011; Schulte et al.,
2011). Mineralized tissue volume that was present only
on the ﬁrst micro-CT scan was considered to be
resorbed/degraded. Mineralized tissue present on both
scans was considered to be quiescent, and a mineralized
tissue that could be found only on the second scan was
considered to be newly mineralized tissue/formed bone.
For an analysis of the spatio-temporal effect, the static
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and dynamic bone parameters were analysed in four
layers of 368μm, each located around the screw. This par-
tition has been shown to furnish useful information about
the peri-implant bone formation and resorption processes
(Kettenberger et al., 2014).
The bone parameters from this study were compared
with the results from animals that were treated with
zoledronate-loaded hydrogel and pure hydrogel during a
previous study (Kettenberger et al., 2014). This compari-
son was used to investigate synergistic effects between
locally delivered nHA and zoledronate, as well as between
hyaluronic acid hydrogel and nHA. Only one static param-
eter, mineralized tissue fraction (MV/TV), was analysed
for this study. The MV/TV values were normalized to
the ﬁrst micro-CT scan (day 3 after screw implantation)
to rule out a bias caused by the nHA that was visible
already on micro-CT of day 3 in the nHA–Gel and he
nHA–Zol–Gel groups. In contrast to our earlier publica-
tion, mineralization rate (bone formation rate) and
demineralization rate (bone resorption rate) were deﬁned
in this study as newly mineralized (formed) and
demineralized (resorbed) bone volume over total bone
volume [over quiescent bone volume in the earlier publi-
cation (Kettenberger et al., 2014)] to be comparable with
other studies.
2.4. Histology
The rat femurs were dissected immediately following
euthanasia at week 58 after screw implantation and ﬁxed,
dehydrated and embedded in PMMA, following a previ-
ously published protocol (Kettenberger et al., 2014). After
polymerization, the sections were cut, glued to PMMA
slides and polished before etching their surface with
0.7 % formic acid (Applichem, Gatersleben, Germany),
then stained with Giemsa (VWR, Dietikon, Switzerland)
or toluidine blue (Promega). Microscopy images for eval-
uation were taken using an upright microscope (DM
5500, Leica Microsystems, Wetzlar, Germany). The
ground sections were ﬁnally X-rayed (Skyscan 1076) for
tissue density mapping.
2.5. Statistics
Statistical testing was done using Matlab (Mathworks,
Natick MA, USA). The Mann–Whitney U-test was used
to evaluate statistical differences in the cell culture assays,
as not all results were normally distributed. The static and
dynamic mineralized tissue parameters were tested for
signiﬁcance using non-parametric Kruskal–Wallis ANOVA
followed by a Tukey’s honestly signiﬁcant difference
(HSD) test, since not all results followed a normal distri-
bution and had an equal variance. Values lying outside
an interval of 1.5 times the quartile range were identiﬁed
as outliers and excluded when analysing the bone
parameters.
3. Results
3.1. In vitro bioactivity of zoledronate-loaded nHA
in osteoclastic precursor cells
A visual inspection of the RAW 264.7 murine macro-
phages via microscopy revealed that these cells were
Figure 2. Light microscopy images of RAW 264.7 murine macrophages after 72 h of incubation with (bottom) and without (top) nHA.
The displayed cells were exposed to a particle concentration that was up to eight times higher than in the cell-culture assay. The
macrophages were able to internalize large amounts of particles (red arrows); in this way they took up all the particles in their direct
surroundings (bottom left). [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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capable of internalizing large amounts of the nanoparti-
cles used in the present study, as they took up all particles
in their direct surroundings (Figure 2). When looking at
the proliferation of the macrophages incubated with
different concentrations of nHA particles dispersed in
the CCM, it can be seen that the nHA particles are well
tolerated by the cells. No signiﬁcant differences from the
control group could be found for both tested concentra-
tions at all three time points (Figure 3). When cultivated
with either a high or a low dose of zoledronate, the
RAW 264.7 macrophages showed a typical dose- and
time-dependent proliferation decrease. This decrease
was signiﬁcant compared to untreated control cells only
for the high zoledronate concentration (5μM) after 24
and 48h, and for both tested concentrations after 72 h
(p<0.05) (Figure 3).
The dose- and time-dependent cell proliferation
decrease was clearly enhanced in the two groups exposed
to nHA loaded with zoledronate compared to the cells
treated with zoledronate alone, indicating a clear
synergistic effect. The difference was statistically signiﬁ-
cant only for the high concentration (5μM) after 24h
and for both tested drug concentrations after 48 and
72h (p<0.01) (Figure 3).
3.2. In vivo study
All rats tolerated both surgeries well and returned to
normal activity right after surgery. The limited food intake
led to a controlled weight gain of the animals; their ﬁnal
mean weight was 384±24g. Analysis of the bone param-
eters based on the micro-CT scans performed before and
after ovariectomy conﬁrmed a successful ovariectomy by
showing a bone loss in all animals that was similar to
the results found before in this model (Kettenberger
et al., 2014) (data not shown).
3.2.1. Micro-CT-based dynamic histomorphometry
A total of 87 micro-CT scans were analysed for the
dynamic histomorphometry, as three had to be excluded
due to motion artefacts. One leg of one animal from the
nHA–Zol–Gel group showed excessive bone formation;
the bone parameters from this leg were identiﬁed as out-
liers and excluded. Five to eight samples/group and for
each time point were left after removal of the outliers.
The rapidity of the appearance and the structure of the
mineralizing tissue that appeared on the micro-CT scans
over time suggested that it could not be entirely attributed
to formed bone (Figure 4). Histology conﬁrmed later that
the hydrogel–nHA composite became mineralized in vivo.
As it was not possible to distinguish on the micro-CT scans
between bone and mineralized biomaterial, we decided to
analyse the mineralization (MR) and demineralization
(DR) rates instead of bone formation and bone resorption
rates, and mineralized tissue volume (MV) instead of
bone volume (BV).
3.2.2. Static parameters
The results from this study were compared with the
results from a previous study, where the hyaluronic acid
hydrogel was implanted either pure (Gel group) or loaded
only with zoledronate but no particles (Zol–Gel group)
Figure 3. Proliferation study with RAW 264.7 macrophages incu-
bated with two concentrations of hydroxyapatite particles (nHA),
pure zoledronate (Zol) or zoledronate-loaded hydroxyapatite
particles (nHA–Zol). The proliferation was measured after 24,
48 and 72 h, using a cell titre assay. The proliferation of cells
treated only with nHA particles did not differ signiﬁcantly from
the control cells at any concentration or time point. Signiﬁcant
differences between the zoledronate-treated cells (Zol) and con-
trol are marked ($p< 0.05). Signiﬁcant differences between the
zoledronate-treated cells (Zol) and the corresponding cells
treated with the same zoledronate concentration and nHA parti-
cles (nHA–Zol) are also marked (*pm 0.01)
Figure 4. Micro-CT scans taken at six time points after surgery from the nHA–Gel group (top) and the nHA–Zol–Gel group (bottom).
In both groups the images show a rapid mineralization of the tissue around the screws, which is resorbed and remodelled quickly in
the nHA–Gel group and persists in the nHA–Zol–Gel group
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(Kettenberger et al., 2014). The analysis of the MV/TV in the
layer next to the screw surface (0–368μm) showed no dif-
ference at any time between the nHA–Zol–Gel and Zol–Gel
groups (Figure 5). In the second layer (368–736μm) the
MV/TV gain was around 50% higher in the nHA–Zol–Gel
than the Zol–Gel group, starting from day 17. However,
a large standard deviation (SD) prevented statistical
signiﬁcance of the results. This difference diminished to
around 30% in the third layer (736–1104μm); again, a
signiﬁcant difference could not be shown, due to high
variability of the results. No difference at all was visible
in the fourth layer (1104–1472μm).
Close to the screw (0–368μm) the nHA in the hydrogel
caused a mineralized tissue fraction gain that was around
30% higher than in the Gel group during the full experi-
mental period. This difference, however, was not statisti-
cally signiﬁcant. In the second layer (368–736μm), the
MV/TV doubled between days 3 and 10, a gain compara-
ble to the zoledronate-treated groups and signiﬁcantly
higher than in the Gel group, which showed a constant
MV/TV. The difference between the nHA–Gel and Gel
groups diminished later in the study and was only mar-
ginal at the end of the experimental period. A similar
development could be observed in the third layer, where
the initial gain in MV/TV was only 50% and the difference
between the nHA–Gel and Gel groups equalled out by day
17. No difference between the nHA–Gel and Gel groups
was found in the outermost layer (1104–1472μm). No
other static bone parameters were analysed for this study,
as all other typical bone parameters would be misleading
when looking at mixture of bone and mineralizing
biomaterial.
3.2.3. Dynamic parameters
The analysis of the dynamic parameters gives information
about bone formation and resorption processes. In the
present study, it was not clear which part of the appearing
mineralized structure could be attributed to new bone
formation and which part to mineralizing biomaterial.
Therefore, we measured a general mineralization rate in-
stead of a bone formation rate, and a demineralization rate
including bone resorption and biomaterial degradation.
Three-dimensional (3D) volume rendering of the compari-
son of two consecutive micro-CT scans was used to get an
overview of the mineralizing and demineralizing processes
(Figure 6). Both experimental groups showed a signiﬁcant
mineralization around the screw between days 3 and 10,
which was followed by a pronounced demineralization in
the nHA–Gel group. The bone further away from the screw
implantation site was also gradually resorbed in this group.
In contrast, the nHA–Zol–Gel group showed only very little
demineralization in the region analysed.
These ﬁndings were also represented in the measured
mineralization and demineralization rates (Figure 7 and 8).
No differences in the mineralization rate in direct
contact with the screw (layer 0–368μm) could be found
between the two groups of this study and the two
groups without nHA from our previous study. In the
second layer (368–736μm), however, between days 3
and 10 there was a highly signiﬁcant difference between
the nHA–Gel and Gel groups and a small trend to a
higher mineralization rate in the nHA–Zol–Gel group
compared to the group that released the drug directly
from the hydrogel (Zol–Gel group). These differences
equalled out by day 10. The same situation could be
found also in the two outer layers (736–1472μm).
A high bone resorption/demineralization was found
between days 10 and 31, which is characteristic for the
drug-free groups. This phenomenon was completely
inhibited by the locally delivered zoledronate (Figure 8).
The demineralization rate of the nHA–Zol–Gel group did
not differ at any time and in any region from that of the
Zol–Gel group. When comparing the nHA–Gel and Gel
Figure 5. Mineralized volume/tissue volume (MV/TV) measured in four layers around the screw: *signiﬁcant differences between the
nHA–Gel and Gel groups; $signiﬁcant differences between the nHA–Zol–Gel and nHA–Gel groups; data from the Zol–Gel and Gel
groups were acquired during an earlier study [1] and are shown for comparison
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groups, there was an unexpected trend to a higher demin-
eralization rate in the nHA–Gel group in the outer two
layers (736–1472μm).
3.3. Histology
The histological results showed that the hyaluronic acid
hydrogel is fully degraded after 58days of implantation
without leaving any visible residues (Figures 9, 10). All
screws showed good osteo-integration without any
inﬂammatory reaction or ﬁbrotic tissue encapsulation. In
both the nHA–Gel and nHA–Zol–Gel groups, highly
mineralized regions were detected within the bone. These
granule-shaped spots had a diameter of up to 50μm in the
nHA–Gel group and extended across wide areas in the
nHA–Zol–Gel group. The X-rays taken of the histology
slides indicated that these granules had a density compa-
rable to/higher than bone. It can be excluded that those
regions simply represented remaining nHA particles, as
the inserted particles had a diameter of<200nm and
the observed granules were much larger.
In the nHA-Gel group, only small amounts of theseminer-
alized spots were found in islands of new bone located
mainly close to the screw tip, the region where the hydrogel
accumulates during screw insertion. The granules were
completely embedded in the bone matrix and the resulting
constructs showed a trabecular structure. No new bone
formation could be detected in this group besides a thin
layer close to the screw surface and the bone close to the
mineralized biomaterial. Almost no trabecular bone was left
around the screw in the nHA–Gel group 13weeks after OVX.
Figure 6. 3D visualization of a comparison of two consecutive micro-CT scans: two representative samples were taken, one from the
nHA–Gel group (top) and one from the Zol–Gel group (bottom); the analysed trabecular region of the bone is shown in light grey, red
and green, and the screw in dark grey; the cortex is transparent. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Figure 7. Mineralization rate (MR), including bone formation and biomaterial mineralization, measured in four layers around the
screw: *signiﬁcant differences between the nHA–Gel and Gel groups; no signiﬁcant differences were found between the nHA–Zol–Gel
and nHA–Gel groups; data from the Zol–Gel and Gel groups were acquired during an earlier study [1] and are shown only for
comparison
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The nHA–Zol–Gel group showed a completely different
situation. Signiﬁcantly larger mineralized regions could
be found, mainly close to the screw tip but also between
the threads. The remaining mineralized biomaterial had
a porous structure and was partly penetrated by bone tis-
sue. In contrast to what was seen in the nHA–Gel group,
the biomaterial–bone constructs were rather compact
and did not show a trabeculae-like structure. In general,
much more trabecular bone could be found both close to
and further away from the screw in the nHA–Zol–Gel
group compared to the nHA–Gel group. New bone was
formed also at the interface to the mineralized hydrogel.
A formation of large periosteal calli was found in the
nHA–Zol–Gel group that was not present to this extent
in the nHA–Gel group.
4. Discussion
The main goal of the present study was to investigate the
bone-reinforcing effect of hydrogel loaded with both
Figure 8. Demineralization rate (DR), including bone resorption and biomaterial degradation, measured in four layers around the
screw: *signiﬁcant differences between the nHA–Gel and Gel groups; $signiﬁcant differences between the nHA–Zol–Gel and nHA–Gel
groups; data from the Zol–Gel and Gel groups were acquired during an earlier study [1] and are shown only for comparison
Figure 9. Toluidine blue-stained ground sections from the nHA–Gel (top) and nHA–Zol–Gel (bottom) groups: * (yellow) in the darker
blue regions indicate immature, non-remodelled bone; ellipses (yellow) on brighter blue regions mark remaining old bone; mineral-
ized hydrogel residues are highlighted with yellow crosses. The small black-and-white panels are X-rays of the histology slides and
show the mineralization of each region. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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hydroxyapatite nanoparticles and the bisphosphonate
zoledronate. An enhanced effect compared to the applica-
tion of only one of the two substances was presumed,
based on studies that demonstrated enhanced peri-
implant bone density after the application of HA particles
(Tami et al., 2009). Furthermore, increased zoledronate
potency in the presence of Ca+ ions has been shown, as
well as a favourable bone ingrowth in BP-linked hydrogel
containing calcium phosphate particles (Monkkonen
et al., 1994; Merrell et al., 2007; Nejadnik et al., 2014).
A cell proliferation assay that was performed with mu-
rine pre-osteoclastic RAW 264.7 macrophages showed a
dose-dependent proliferation decrease for cells exposed
to zoledronate. This result conﬁrms the ﬁndings of Abe
et al. (2012), who showed that nitrogen-containing BPs
are cytotoxic for RAW 264.7 cells. The inhibitory effect
of zoledronate was signiﬁcantly enhanced by the presence
of nHA particles, which were added to the solution at a
nHA:zoledronate ratio of 10:1, indicating a clear synergis-
tic effect between the two compounds. Due to the high
afﬁnity of zoledronate to hydroxyapatite, it must be as-
sumed that most of the zoledronate was absorbed to the
particles and therefore not present in solution (Nancollas
et al., 2006). Light microscopy images showed that the
macrophages internalized the zoledronate-loaded parti-
cles surrounding them. This ﬁnding suggests that the cells
had taken up the drug together with the nHA particles.
Thompson et al. (2006) showed that amino-BPs are
typically internalized by macrophages and osteoclasts via
ﬂuid-phase endocytosis (pinocytosis) in vitro. Particles,
however, have been shown to be incorporated by macro-
phages via pinocytosis only for sizes<500nm; larger
particles are phagocytosed (Kruth et al., 2005; Oh and
Park, 2014). The particles used for this study had a size
of<200nm but formed agglomerations, so that both
mechanisms have to be considered. A stronger inhibitory
effect on macrophages has also been described for
BP-modiﬁed gold nanoparticles (size<100nm) compared
to unbound BP (Fanord et al., 2011). One possible
explanation is a more speciﬁc intracellular accumulation
of drug molecules at the site of action with the particles
as carrier. In our study, an alternative explanation could
be an enhancement of the BP potency by the presence of
calcium, a phenomenon that has been demonstrated
previously (Thompson et al., 2006). The Ca+ ions could
originate from hydroxyapatite digestion by lysosomal
enzymes in the macrophages (Bloebaum et al., 1998). In
order to rule out a negative effect of the nHA powder
itself on the macrophages, we also cultured them only
with particles. The results showed that the cells tolerated
the presence of the particles well, a ﬁnding that has been
published previously (Scheel et al., 2009).
An unexpected original ﬁnding of this study was the
rapid in vivo mineralization of the hydrogel, which hap-
pened independently of the BP in both experimental
groups. It is known that calcium phosphate particles can
act as nucleation sites in hydrogel matrices, promoting
HA precipitation (Gkioni et al., 2010). This phenomenon
has been investigated mainly in vitro with simulated body
ﬂuids (Chen et al., 2011). We could not ﬁnd any publica-
tions showing such a rapid mineralization in vivo.
Nejadnik et al. (2014) recently published a study investi-
gating the use of pure and BP-modiﬁed hyaluronic acid
with calcium phosphate nanoparticles for bone repair.
Despite a mineral content of the gel in the same range
(6 vs 10w/v% in the present study), they did not report
a considerable mineralization of the hydrogels after
4weeks of implantation in bony defects created in rat
tibiae. However, in their study newly formed bone
was analysed based only on histology. Depending on the
staining used, histology might not be the most
appropriate technique to detect biomaterial mineralization.
The highly mineralized spots that were found in the
present study mainly showed a granule-like structure with
a particle size of up to 50μm, which supports the concept
that they were formed by hydroxyapatite deposition,
starting from the nHA particles as nucleation points. In
the nHA–Zol–Gel group, the granules seemed even to
have fused to larger mineralized regions, as shown by his-
tology. A complete integration of the newly formed
granules into the bone matrix without any signs of inﬂam-
mation or foreign body reaction conﬁrmed their excellent
biocompatibility and osteoconductivity. When comparing
the nHA–Gel group of this study with the Gel group of a
former study, signiﬁcant differences in early mineraliza-
tion could be detected. The explanation for this phenom-
enon is an initial rapid mineralization of the biomaterial,
followed by its simultaneously occurring degradation
Figure 10. Details from the samples shown in Figure 9. The sections were stained with Giemsa for a better differentiation between
bone (pink) and mineralized hydrogel (pink-brownish): (left) small granule-shaped mineralized spots from the nHA–Gel group are
marked with yellow arrows; (right) an extended mineralized region from the nHA–Zol–Gel group is marked with a yellow line;
smaller regions are also highlighted with yellow arrows. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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and penetration by bone tissue, as shown by structural
changes on the time-lapse micro-CT scans and the termi-
nal histology results. Lower amounts of residual mineral-
ized spots in the nHA–Gel group compared to the
nHA–Zol–Gel group indicate an efﬁcient biodegradation
of the HA. Similar ﬁndings have been published by Arts
et al. (2006), who demonstrated that HA nano-powder
is integrated in newly formed bone and efﬁciently recruits
macrophages and osteoblasts in vivo.
The obvious mineralization of the biomaterial compli-
cated evaluation of the drug effect on peri-implant bone.
In vivo micro-CT imaging did not allow a differentiation
between newly formed woven bone and mineralized hy-
drogel. When comparing the mineralized tissue volume
fraction and the mineralization rate of the nHA–Zol–Gel
group to the Zol–Gel group of an earlier study
(Kettenberger et al., 2014), no signiﬁcant differences
could be detected at any time. However, there was a
strong trend to more tissue mineralization that appeared
early and remained visible during the whole experimental
phase. Contributors to this gain of mineralized tissue
could have been, on the one hand, new woven bone for-
mation and, on the other hand, biomaterial mineraliza-
tion. In our earlier study we stated that the discovered
boost in early peri-implant bone formation was caused
by an initial ’ﬂush’ of all bone cells with BP
(Kettenberger et al., 2014). We did not investigate the
release of particles from the gel, as it is highly depen-
dent on the shape, swelling state and surrounding tissue
of the hydrogel and is therefore difﬁcult to mimic
in vitro. However, it can be assumed that the release
of the comparatively huge nHA particles is signiﬁcantly
slower than that of the small drug molecules. Orriss
et al. (2009) showed in vitro that an inhibitory effect
on osteoblast mineralization of bound zoledronate oc-
curred at 10–100-fold higher concentrations compared
to free zoledronate. As the non-phagocytic osteoblasts
are unlikely to incorporate zoledronate-loaded particles,
less inﬂuence on bone formation can be assumed for the
nHA–Zol–Gel group compared to the situation when
zoledronate is delivered from pure hydrogel (Zol–Gel
group). This theory is also supported by the ﬁndings
of Arslan et al. (2011), who could not ﬁnd a signiﬁcant
inﬂuence of alendronate-soaked HA granules on bone
formation compared to saline-soaked HA in a OVX
mandibular defect model. Nevertheless, small but still
signiﬁcant differences could also be shown for the min-
eralization rate between the nHA–Gel and nHA–Zol–Gel
groups. As a consequence, the zoledronate–nHA combi-
nation must inﬂuence bone formation and/or biomate-
rial mineralization in a different way from pure nHA;
however, the mechanism is not clear.
When looking at the demineralization rate, the strong
inhibitory effect of zoledronate becomes obvious in the
highly signiﬁcant differences between the nHA–Gel and
nHA–Zol–Gel groups. The micro-CT study and histology
revealed that the drug not only inhibited bone resorption
but also biomaterial degradation, as can be seen by the
absence of macrophages and giant foreign body cells
and much larger amounts of mineralized material remain-
ing in the nHA–Zol–Gel group. Histology also showed that
the bone–biomaterial construct in the nHA–Gel group
had already been remodelled to a trabecular structure,
whereas it was still rather compact in the nHA–Zol–Gel
group. There was no difference in the demineralization
rate between the Zol–Gel group from the former study
and the nHA–Zol–Gel group from the present study, even
further away from the screw. Therefore, there must be
either a release of the drug-loaded particles or a release
of the drug alone, as it can be caused by the resorptive
activity of surviving osteoclasts or macrophages (Coxon
et al., 2006). Unfortunately, the present study could not
give any answer to the question of by which means and
how far the drug-loaded particles move in the bone envi-
ronment in vivo.
Micro-CT-based histomorphometry was chosen for the
present study as we found it to be a very suitable tech-
nique for the long-term 3D analysis of peri-implant bone
remodelling (Kettenberger et al., 2014). The unexpected
rapid mineralization found in the present study, however,
interfered with the bone analysis, which is one inherent
limitation of this study. The differentiation between bone
and biomaterial can only be done by means of histology,
which was scheduled for this study only at the end of
the experimental period of 8weeks. Future studies should
therefore include more groups of animals so that
histology can be performed at earlier time points for an
observation of synergies between bone formation and bio-
material mineralization. More experiments are also
needed to understand the exact mineralization processes
and the composition and mechanical competence of the
resulting mineral. The in vivo mineralization seems to be
dependent on size, shape and material of the particles,
as well as on type, density and degradation proﬁle of the
hydrogel, as similar studies with comparable materials
did not report an in vivo mineralization (Nageeb et al.,
2012; Martínez-Álvarez et al., 2013; Heo et al., 2014;
Nejadnik et al., 2014). An investigation of the mechanical
properties of the resulting material, as could be done by
nano-indentation, will be key when it comes to an evalu-
ation of implant stability. Another limitation of this study
was the fact that the rats received the same material in
both femoral condyles. Ideally, two different materials
are implanted in one animal to improve the inter-sample
variability; however, this was not done in the present
study, in order to avoid a systemic effect of zoledronate
on the contralateral side.
The hydrogels containing pure or zoledronate-loaded
nHA particles were both easy to apply to bone, due to
their soft consistency, which makes them ideal for an ap-
plication to irregular-shaped cavities such as an implant
bed or difﬁcult-to-access bone defects. The indications
for both materials, however, should still not be the same.
The nHA-loaded hydrogel induced some new bone forma-
tion within the biomaterial in the present study, but was
not able to stabilize the bone loss characteristic for OVX
rats (Kettenberger et al., 2014). The nHA-loaded hydrogel
could therefore have more potential in the repair and
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sealing of bony defects in healthy bone. The hydrogel with
nHA and zoledronate, however, could be favourable for
the repair of bone defects that require at the same time
a preservation of the surrounding bone matrix. Attention
has to be paid in this case to the drug dose and the density
of the resulting mineralized spots. As zoledronate has a
’protective’ effect for the biomaterial and inhibits its deg-
radation, there is a risk that penetration by the bone tissue
can become impossible if the biomaterial densiﬁes too
much and cannot be resorbed.
Despite the synergistic effects between hydroxyapatite
nanoparticles and zoledronate that we were able to show
in vitro, it was not possible to answer the question of
whether the use of a nHA–zoledronate hydrogel further
improves implant ﬁxation compared to a hydrogel loaded
only with zoledronate (Kettenberger et al., 2015). There
was a non-signiﬁcant increase of the mineralized tissue
volume fraction in an extended range around the implant,
but large amounts of biomaterial residues with unknown
mechanical properties require mechanical testing before
drawing a ﬁnal conclusion. For the moment we can only
conclude that both tested materials seem to be good
candidates for bone repair in different speciﬁc clinical
situations.
5. Conclusion
The present study was able to show a synergistic effect
between zoledronate and nHA particles in vitro, as the
inhibitory effect of the drug on osteoclast precursors was
enhanced when administering zoledronate absorbed on
hydroxyapatite nanoparticles. Furthermore, it could be
demonstrated that nano-sized hydroxyapatite can serve
as nucleation points in hyaluronic acid hydrogel in vivo
in a rat model of postmenopausal osteoporosis. The mate-
rial is then rapidly mineralizing under the formation of
μm-sized granules. These highly mineralized spots have
been shown to be highly biocompatible, biodegradable
and to serve as scaffolds for new bone formation. The bio-
material mineralization also occurred when zoledronate
was absorbed to the nanoparticles before integrating
them into the hydrogel. In this case, however, the forming
granules were protected from degradation by the anti-
resorptive effect of the BP resulting in larger mineralized
regions compared to drug-free nHA–hydrogel. At the
same time, zoledronate was still active and efﬁciently
inhibited the resorption of peri-implant bone to a similar
extent to pure hydrogel loaded only with the drug.
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